RYBREVANT (amivantamb)
TherapyJohnson & Johnson
RYBREVANT (amivantamab) from Johnson & Johnson is a bispecific antibody used in EGFR exon 20 insertion–positive lung cancer.
Approvals
2
Indications
1
Biomarkers
1
Mapped tests
2
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and RYBREVANT. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where RYBREVANT is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | EGFR (HER1)
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for RYBREVANT.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering RYBREVANT for eligible patients.
Test
Guardant360 CDx
Guardant Health, Inc.
Method
NGS
Specimen
Plasma
1 approvalView test profile →
Test
Oncomine Dx Target Test
Life Technologies Corporation (ThermoFisher Scientific)
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →